156 related articles for article (PubMed ID: 35227733)
1. Redox-responsive nanoparticles enhance radiation therapy by altering multifaceted radio-resistance mechanisms in human castration-resistant prostate cancer cells and xenografts.
Lip H; Amini MA; Zetrini A; Cai P; Abbasi AZ; Bristow RG; Rauth AM; Wu XY
Radiother Oncol; 2022 May; 170():213-223. PubMed ID: 35227733
[TBL] [Abstract][Full Text] [Related]
2. Remodeling Tumor Immune Microenvironment by Using Polymer-Lipid-Manganese Dioxide Nanoparticles with Radiation Therapy to Boost Immune Response of Castration-Resistant Prostate Cancer.
Zetrini AE; Lip H; Abbasi AZ; Alradwan I; Ahmed T; He C; Henderson JT; Rauth AM; Wu XY
Research (Wash D C); 2023; 6():0247. PubMed ID: 37795337
[TBL] [Abstract][Full Text] [Related]
3. Microwave hyperthermia enhances radiosensitization by decreasing DNA repair efficiency and inducing oxidative stress in PC3 prostatic adenocarcinoma cells.
Wu Y; Liu P; Chen W; Bai S; Chen S; Chen J; Xu X; Xia J; Wu Y; Lai J; Sun C; Lao Z; Wan X; Wu Z
Int J Hyperthermia; 2024; 41(1):2335201. PubMed ID: 38583875
[TBL] [Abstract][Full Text] [Related]
4. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
5. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of a redox-silent analogue of tocotrienol on hypoxia adaptation in prostate cancer cells.
Shiozawa N; Sugahara R; Namiki K; Sato C; Ando A; Sato A; Virgona N; Yano T
Anticancer Drugs; 2017 Mar; 28(3):289-297. PubMed ID: 27926612
[TBL] [Abstract][Full Text] [Related]
8. Salicylate enhances the response of prostate cancer to radiotherapy.
Broadfield LA; Marcinko K; Tsakiridis E; Zacharidis PG; Villani L; Lally JSV; Menjolian G; Maharaj D; Mathurin T; Smoke M; Farrell T; Muti P; Steinberg GR; Tsakiridis T
Prostate; 2019 Apr; 79(5):489-497. PubMed ID: 30609074
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of EGFR and HER2 against prostate cancer stem cells.
Rossini A; Giussani M; Ripamonti F; Aiello P; Regondi V; Balsari A; Triulzi T; Tagliabue E
Cancer Biol Ther; 2020 May; 21(5):463-475. PubMed ID: 32089070
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
12. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
13. The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
Nesbitt H; Worthington J; Errington RJ; Patterson LH; Smith PJ; McKeown SR; McKenna DJ
Prostate; 2017 Nov; 77(15):1539-1547. PubMed ID: 28944496
[TBL] [Abstract][Full Text] [Related]
14. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways.
Zhou S; Dai Z; Wang L; Gao X; Yang L; Wang Z; Wang Q; Liu Z
J Cell Mol Med; 2021 Dec; 25(24):11157-11169. PubMed ID: 34761497
[TBL] [Abstract][Full Text] [Related]
15. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.
Benelli R; Barboro P; Costa D; Astigiano S; Barbieri O; Capaia M; Poggi A; Ferrari N
Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816863
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
17. Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3.
Ma B; Zhang H; Wang Y; Zhao A; Zhu Z; Bao X; Sun Y; Li L; Zhang Q
J Exp Clin Cancer Res; 2018 Sep; 37(1):210. PubMed ID: 30176898
[TBL] [Abstract][Full Text] [Related]
18. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
19.
Kim S; Sundaram A; Mathew AP; Hareshkumar VS; Mohapatra A; Thomas RG; Bui TTM; Moon K; Kweon S; Park IK; Jeong YY
Biomater Sci; 2023 Sep; 11(18):6177-6192. PubMed ID: 37504889
[TBL] [Abstract][Full Text] [Related]
20. S100A3 suppression inhibits in vitro and in vivo tumor growth and invasion of human castration-resistant prostate cancer cells.
Kang M; Lee HS; Lee YJ; Choi WS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Urology; 2015 Jan; 85(1):273.e9-15. PubMed ID: 25440760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
